EB2-NIW Approved!
Another powerful success story!
We’re thrilled to announce that our exceptional client has officially received EB2-NIW approval, affirming the national importance of her work in scaling individualized cancer immunotherapies and strengthening U.S. biopharmaceutical manufacturing.
| Processing Type | Premium Processing |
| Priority Date | March 6, 2026 |
| I-140 Approved | April 30, 2026 |
| Immigration Status | H-1B Visa |
| Field of Expertise | Manufacturing Science & Technology (MS&T) for Biopharmaceuticals — technology transfer, cGMP manufacturing, lipid nanoparticle (LNP) process engineering, and Lean Six Sigma–driven process optimization for mRNA vaccines and personalized cancer therapies |
| Degrees | Master of Science, Pharmaceutical Engineering Bachelor of Engineering, Chemical Engineering |
Professional Highlights
- Engineer III at a leading U.S. mRNA biopharmaceutical manufacturer, with progressive growth from Manufacturing Associate I to Manufacturing Associate II, then Engineer II, and now Engineer III
- Prior R&D Associate Scientist experience supporting upstream research and development
- Lean Six Sigma Green Belt and Yellow Belt certified
- Active member of the International Society for Pharmaceutical Engineering (ISPE)
- Published peer-reviewed research on cell-free protein synthesis
- Featured in Illinois Tech coverage of COVID-19 vaccine manufacturing
Key Achievements
- 8% increase in downstream manufacturing yield
- 10% reduction in batch turnaround time
- Led full-cycle technology transfer of an individualized melanoma immunotherapy program
- Contributed to commercial-scale production of an mRNA COVID-19 vaccine during the U.S. pandemic response
- Developed FDA-compliant SOPs under cGMP standards
- Drove process optimization using DMAIC and FMEA methodologies
- 6 recommendation letters, including 2 from independent industry experts (Distinguished Scientist at Sanofi; Head of Microbiology at CP Kelco)
- 15+ policy and national importance references in the petition record
Why This Petition Succeeded
Substantial Merit & National Importance. The endeavor was tied directly to the White House Cancer Moonshot Initiative, federal executive orders on domestic biomanufacturing, the HHS Skin Cancer Prevention Strategy, and U.S. public health supply chain resilience — supported by CDC data, American Cancer Society statistics, and federal economic impact reports.
Well Positioned to Advance the Endeavor. Progressive technical roles at a leading mRNA manufacturer, quantified process improvements, FDA-compliant SOP authorship, and independent expert validation established her as uniquely qualified to deliver on the proposed work.
Labor Certification Waiver Justified. Specialized expertise in cGMP technology transfer and LNP process engineering, combined with documented U.S. workforce shortages and federal biomanufacturing priorities, demonstrated impact reaching well beyond any single employer.
Proposed Endeavor
Building scalable, FDA-compliant biopharmaceutical manufacturing platforms that move individualized melanoma immunotherapies from laboratory research into reliable, large-scale production across multiple U.S. sites — improving access to life-saving cancer treatments while lowering cost per dose.
